Is it safe to wait? The effect of surgical wait time on survival in patients with non–small cell lung cancer

Coughlin, Shaun; Plourde, Madelaine; Guidolin, Keegan; Fortin, Dalilah; Fréchette, Éric; Malthaner, Richard; Inculet, Richard

doi:10.1503/cjs.007015

Cited by 27 publications

(31 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have demonstrated that shorter delays are associated with shorter survival, perhaps reflecting expedited investigation and treatment of advanced disease and greater numbers of symptomatic cases [16][17][18] . In contrast, other reports showed that longer time to treatment was a significant negative prognostic factor in patients with stage iii disease and an os of 5 or more years 19 and in those with stage ii disease undergoing surgical resection 20 . Almost all those studies were retrospective and had small sample sizes.…”

Section: Introductionmentioning

confidence: 79%

Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 79%

Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Canadian study showed that for Stage II NSCLC, wait time greater than 2 months adversely affected survival. 14 Both operative time and incidence of intraoperative complications were significantly higher in the biopsy cohort (Table 4). There are several possible explanations for these findings.…”

Section: Discussionmentioning

confidence: 97%

“…Some studies show that delay in treatment does not significantly impact overall prognosis of early stage NSCLC . However, a recent Canadian study showed that for Stage II NSCLC, wait time greater than 2 months adversely affected survival . Certainly minimizing wait time may also alleviate patient and family anxiety …”

Section: Discussionmentioning

confidence: 99%

Is tissue still the issue? Lobectomy for suspicious lung nodules without confirmation of malignancy

Kaaki

Kidane

Srinathan

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…NSCLC is the most common malignancy in the respiratory system, accounting for about 80% of all lung cancers. The current treatment for NSCLC includes surgery, radiotherapy and chemotherapy, with surgery being the most effective treatment [13]. However, due to the fact that early diagnosis is unavailable, many patients were diagnosed as advanced lung cancer with metastasis, therefore missing the opportunity for surgical treatment.…”

Section: Discussionmentioning

confidence: 99%

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH

et al. 2020

View full text Add to dashboard Cite

Cisplatin-based chemotherapy is the standard treatment for non-small cell lung cancer (NSCLC). However, drug resistance emergences after treatment. Long non-coding RNA microvascular invasion in hepatic cancer (MVIH) plays an important role in drug resistance in a variety of cancers. This study investigates the role of nedaplatin on multidrug resistance in NSCLC and its relationship with MVIH. Lung cancer A549 and H1650 cells were treated with cisplatin to obtain multidrug-resistant A549/DDP and H1650/ DDP cells. A549/DDP and H1650/ DDP cells were treated with nedaplatin, MVIH siRNA and siRNA NC. It was found that both MVIH siRNA and nedaplatin significantly reduce the mRNA expression of MVIH in A549/DDP and H1650/ DDP cells. MTT assay showed that the proliferation of MDR cells was significantly higher than that of other cells. Nedaplatin and MVIH siRNA significantly inhibit the proliferation of A549 and H1650 cells. The results of colony formation assay were consistence with MTT results. Nedaplatin and MVIH siRNA significantly reduced colony formation in MDR cells. Flow cytometry showed that NDP and MVIH siRNA significantly decrease the proportion of cells in G0/G1 and increase the proportion of cells in S phase compared with untreated and MDR cells. The apoptotic rate of MDR cells was significantly lower than that of other cells, while the apoptosis rate of cells in NDP and MVIH siRNA group was significantly higher than that of the other three groups of cells. Wound healing assay and Transwell chamber experiments confirmed that both NDP and MVIH siRNA significantly reduced the migration and invasion abilities of MDR cells. The expression of E-cadherin in MDR cells was significantly lower than that in untreated cells, and the expression of N-cad, α-SMA and Vimentin significantly increased in the MDR cells. NPD and MVIH siRNA reverse the EMT process. In conclusion, LncRNA MVIH is upregulated in drug resistant NSCLC cells. Nedaplatin can reduce the expression of MVIH and reverse EMT process, thus reversing the drug resistance of cisplatin in non-small cell lung cancer cells.

show abstract

Is it safe to wait? The effect of surgical wait time on survival in patients with non–small cell lung cancer

Cited by 27 publications

References 7 publications

Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

Is tissue still the issue? Lobectomy for suspicious lung nodules without confirmation of malignancy

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH

Contact Info

Product

Resources

About